A new drug regimen for certain types of pancreatic cancer recently received approval from the U.S. Food and Drug Administration (FDA) — the first new medication in nearly a decade.
A new drug regimen for certain types of pancreatic cancer recently received approval from the U.S. Food and Drug Administration (FDA) — the first new medication in nearly a decade. Onivyde (irinotecan liposome), an injectable medication made by Ipsen, has been approved for use along with oxaliplatin, fluorouracil and leucovorin as a regimen for patients with metastatic pancreatic adenocarcinoma (mPDAC).
This type of cancer is an aggressive malignancy with an average life expectancy of between eight and 11 months, according to the National Institutes of Health (NIH). ON THIS DAY IN HISTORY, MARCH 6, 2019, ALEX TREBEK SHARES CANCER DIAGNOSIS WITH THE WORLD The approval was based on a randomized, controlled trial that included 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy, according to an FDA press releas
Drug Regimen Pancreatic Cancer FDA Approval Onivyde Metastatic Pancreatic Adenocarcinoma
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Issues New Guidance for Early Alzheimer's Drug DevelopmentThe FDA embraces the use of biomarkers and surrogate endpoints in its most recent guidance on developing therapeutics for early Alzheimer’s disease.
Read more »
FDA Okays New Drug for Resistant HypertensionAprocitentan is the first endothelin receptor antagonist approved to lower blood pressure, in combination with other antihypertensives, in treatment-resistant hypertension.
Read more »
A New Generation of Drug Therapies Requires New Business StrategiesThe shift to advanced therapeutic modalities (ATMs) promises to change the nature of competition in the pharmaceuticals industry.
Read more »
FDA Approves First Drug-Coated Balloon to Treat Coronary In-Stent RestenosisThe Agent DCB, from Boston Scientific, was superior to uncoated balloon angioplasty for the treatment of coronary artery in-stent restenosis in a pivotal trial.
Read more »
In an unusual move, FDA postpones approval decision for Lilly’s Alzheimer’s drugBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly's Alzheimer's drug delayed by FDA: ‘It was unexpected’On Friday, the FDA announced it would postpone a decision on Eli Lilly's potential Alzheimer's treatment donanemab.
Read more »